TaiGen Announces Presentation of Nemonoxacin at the Joint Meeting of ICAAC/IDSA

TAIPEI, Taiwan--(BUSINESS WIRE)--Oct 20, 2008 - Taipei, Taiwan -October 20 2008 - TaiGen Biotechnology Co., Ltd. today announced a total of 11 posters on its investigational drug nemonoxacin will be presented at the joint 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) / 46th Annual Meeting of Infectious Diseases Society of America (IDSA) to be held in Washington, D.C. from October 25 - 28, 2008.

Nemonoxacin, a non-fluorinated quinolone, has an exceptional activity against MRSA (Methicilin-Resistant Staphylococcus aureus). Particular activity was demonstrated toward community-acquired MRSA, an emerging concern of the public health. The drug has an excellent activity toward vancomycin-intermediate or resistant Staphylococcus aureus. In a comparative in vitro study with other quinolones in clinical use, nemonoxacin is less prone to the development of resistance and is active against quinolone-resistant clinical strains.

The top-rated phase 2 data of a randomized double-blind trial in comparison to levofloxacin will be reported. Nemonoxacin met the primary endpoints of non-inferiority to levofloxacin in both cure rate and safety. Patient enrollment for the second phase 2 trial of diabetic foot infection (DFI) is on-going to demonstrate the anti-MRSA activity with oral administration of nemonoxacin. -0-

Clinical
----------------------------------------------------------------------
Saturday, October 25, 12:15 pm - 1:15 pm
Poster Session # 44: The World of Community-Acquired Pneumonia
Presentation # L678: Efficacy and Safety of Nemonoxacin versus
 Levofloxacin for the Treatment of Community-Acquired Pneumonia

Microbiological
----------------------------------------------------------------------
Saturday, October 25, 12:15 pm - 1:15 pm
Poster Session # 12: Staphylococcus aureus: MRSA and More
Presentation # C1-189: Comparative Antistaphylococcal activity of
 Nemonoxacin, a Novel Broad-spectrum Quinolone

Saturday, October 25, 12:15 pm - 1.:15 pm
Poster Session # 16: Resistance in Streptococcus pneumoniae
Presentation # C2-254: In Vitro Activity of Nemonoxacin (TG-873870), a
 Novel Non-Fluorinated Quinolone, against Clinical Isolates of
 Streptococcus pneumoniae in Taiwan

Monday, October 27, 11:15 a.m. - 12:15 p.m
Poster Session # 189. Quinolones
Presentation # C1-1957: Activity of Nemonoxacin, an Investigational
 C8-methoxy Non-fluorinated Quinolone, Against Gram-Negative Bacilli
 Obtained From Canadian Hospitals: CANWARD 2007

Monday, Oct 27, 2008, 11:15 a.m. -12:15 p.m.
Poster Session # 190: Respiratory, Skin, and Genital Infections
Presentation # C1-1971: In Vitro Resistance Development to Nemonoxacin
 for Streptococcus pneumoniae

Monday, October 27, 11:15 a.m. - 12:15 p.m
Poster Session # 195. New Topoisomerase Inhibitors
Presentation # F1-2057: Activity of Nemonoxacin, an Investigational
 C8-methoxy Non-fluorinated Quinolone Against Gram-Positive Cocci
 Obtained From Canadian Hospitals: CANWARD 2007

Tuesday, Oct 28, 2008, 11:15 a.m. -12:15 p.m.
Poster Session # 286: Surveys of Susceptibility Testing and Resistance
Presentation # C2-3931: In Vitro Activity of Nemonoxacin against
 Helicobacter pylori

In vivo Efficacy Model
----------------------------------------------------------------------
Saturday, Oct 25, 2008, 12:15 p.m. - 1:15 p.m.
Poster Session # 6: Therapy of Bacterial Infections in Animal Models
Presentation # B-056: In Vivo Efficacy of Nemonoxacin in a Mouse
 Pulmonary Infection Model

Sunday, Oct 26, 2008, 11:15 a.m. -12:15 p.m.
Poster Session #93: Antistaphylococcal Therapy Testing in Animal
 Models
Presentation # B-1005: In Vivo Efficacy of Nemonoxacin in a Mouse
 Protection Model

Safety Assessment
----------------------------------------------------------------------
Monday, Oct 27, 2008, 11:15 a.m. -12:15 p.m.
Poster Session # 195: New Topoisomerase Inhibitors
Presentation # F1-2055: Systemic Hypersensitivity Test of Nemonoxacin,
 a Novel Potent Broad-Spectrum Non-Fluorinated Quinolone, in Guinea
 Pigs

Monday, Oct 27, 2008, 11:15 a.m. -12:15 p.m.
Poster Session # 195: New Topoisomerase Inhibitors
Presentation # F1-2056: Fertility and Early Embryonic Developmental
 Toxicity of Nemonoxacin after Oral Administration to Rats

These data and their reception by the conference program committee highlight the potential of nemonoxacin's to become a potent novel drug to treat some of the most threatening multi-drug resistant bacteria infection.

About TaiGen Biotechnology Co., LTD

TaiGen Biotechnology (http://www.taigenbiotech.com/) is a leading development stage pharmaceutical company based in Taiwan with a wholly-owned subsidiary in Beijing, China. The company is developing novel therapeutics to treat infectious diseases, diabetic complications and cancer for the worldwide market. TaiGen has a full capacity in new drug R&D and clinical development in China, Taiwan, US and other countries. The company's in-house R&D has developed first-in-class drug candidates and the first such drug, TG-0054, is currently in phase 1 trial in the US. TaiGen plans to develop TG-0054 for stem cell transplantation, critical limb ischemia and age-related macular degeneration. Nemonoxacin, a broad-spectrum non-fluorinated quinolone achieved the non-inferiority clinical cure rate compared with levofloxacin and two drugs have comparable safety profile in the phase II trial. Patient enrollment for the second phase II trial in nemonoxacin with diabetic foot infection (DFI) will soon initiate to demonstrate anti-MRSA activity with oral administration of nemonoxacin.

TaiGen plans to commercialize the nemonoxacin in greater China and ASEAN countries. The company will out-license nemonoxacin for the US/EU/Japan market with P&G Pharmaceuticals. The "First-class New Drug" trials in China are on-going and product projected to launch in 2011. TaiGen has advanced programs in preclinical development for chronic hepatitis C infection (target at the viral protease) and solid tumors.

Contact

TaiGen Biotechnology Co., Ltd.
Gloria Hsieh, Ph.D., +886-2-2790-1861 ext. 1722
Director, Public Relation & Business Development
Fax: +8862-2790-9962
gloriahsieh@taigenbiotech.com.tw

 

Posted: October 2008

View comments

Hide
(web5)